Better design leads to better results - Importance of virological outcome design in clinical trials for antiviral treatment of coronavirus disease 2019.
作者信息
Zhaori Getu, Lu Lu, Liu Chunyan, Han Shujing, Guo Yongli
机构信息
Editorial Office Pediatric Investigation, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health Beijing China.
Medical Journal Center Beijing Pediatric Research Institute Beijing Children's Hospital Capital Medical University National Center for Children's Health Beijing China.
出版信息
Pediatr Investig. 2023 Jan 9;7(1):1-5. doi: 10.1002/ped4.12363. eCollection 2023 Mar.
Abstract
摘要
相似文献
1
Better design leads to better results - Importance of virological outcome design in clinical trials for antiviral treatment of coronavirus disease 2019.更好的设计带来更好的结果——2019冠状病毒病抗病毒治疗临床试验中病毒学结果设计的重要性。
Pediatr Investig. 2023 Jan 9;7(1):1-5. doi: 10.1002/ped4.12363. eCollection 2023 Mar.
2
Nitazoxanide for chronic hepatitis C.硝唑尼特用于慢性丙型肝炎
Cochrane Database Syst Rev. 2014 Apr 6;2014(4):CD009182. doi: 10.1002/14651858.CD009182.pub2.
3
Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.抗冠状病毒 2019 病的抗病毒药物的临床疗效：一项随机对照试验的系统评价。
J Microbiol Immunol Infect. 2021 Oct;54(5):767-775. doi: 10.1016/j.jmii.2021.05.011. Epub 2021 Jun 26.
4
Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.聚乙二醇干扰素联合利巴韦林与干扰素联合利巴韦林治疗慢性丙型肝炎的比较
Cochrane Database Syst Rev. 2014 Feb 28;2014(2):CD005441. doi: 10.1002/14651858.CD005441.pub3.
5
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.洛匹那韦/利托那韦在严重急性呼吸综合征治疗中的作用：初步病毒学及临床研究结果
Thorax. 2004 Mar;59(3):252-6. doi: 10.1136/thorax.2003.012658.
6
[Compound Chinese herbal medicines, Chinese herbal drugs and their active extracts for treatment of chronic hepatitis C: a systematic review and meta-analysis of randomized clinical trials].用于治疗慢性丙型肝炎的复方中药、中草药及其活性提取物：随机临床试验的系统评价和荟萃分析
Zhong Xi Yi Jie He Xue Bao. 2009 Oct;7(10):913-28. doi: 10.3736/jcim20091003.
7
Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019.患有晚期慢性肾脏病和2019冠状病毒病患者使用奈玛特韦-利托那韦治疗的安全性、临床及病毒学结果
Clin Infect Dis. 2023 Nov 17;77(10):1406-1412. doi: 10.1093/cid/ciad371.
8
Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study.随机对照试验中合理样本量检测 COVID-19 有显著抗病毒药物作用：建模研究。
PLoS Med. 2021 Jul 6;18(7):e1003660. doi: 10.1371/journal.pmed.1003660. eCollection 2021 Jul.
9
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.直接抗病毒药物治疗后的临床结局：超越既往丙型肝炎病毒相关失代偿性肝硬化患者的病毒学应答
BMC Infect Dis. 2022 Jan 27;22(1):94. doi: 10.1186/s12879-022-07076-0.
10
Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs.新型冠状病毒 2019 抗病毒药物临床试验的发展与进展。
Expert Rev Clin Pharmacol. 2020 Sep;13(9):945-956. doi: 10.1080/17512433.2020.1803740. Epub 2020 Aug 12.
引用本文的文献
1
Importance of sample size determination for randomized controlled clinical trials for coronavirus disease 2019 antiviral therapies.2019冠状病毒病抗病毒疗法随机对照临床试验中样本量确定的重要性。
Pediatr Investig. 2024 Jan 24;8(1):7-11. doi: 10.1002/ped4.12415. eCollection 2024 Mar.
2
A new column in this journal - Forum on Clinical Investigation.本刊新设栏目——临床研究论坛。
Pediatr Investig. 2023 May 9;7(2):147-149. doi: 10.1002/ped4.12378. eCollection 2023 Jun.
本文引用的文献
1
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.在一项针对非住院 COVID-19 成年患者的随机试验中，巴洛沙韦单抗的抗病毒和临床活性。
Nat Commun. 2022 Aug 22;13(1):4931. doi: 10.1038/s41467-022-32551-2.
2
Therapeutic monoclonal antibodies for COVID-19 management: an update.治疗 COVID-19 的单克隆抗体：最新进展。
Expert Opin Biol Ther. 2022 Jun;22(6):763-780. doi: 10.1080/14712598.2022.2078160. Epub 2022 May 29.
3
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.瑞德西韦和其他三种药物治疗 COVID-19 住院患者：世卫组织团结随机试验的最终结果和更新的荟萃分析。
Lancet. 2022 May 21;399(10339):1941-1953. doi: 10.1016/S0140-6736(22)00519-0. Epub 2022 May 2.
4
Efficacy and Safety of SARS-CoV-2 Neutralizing Antibody JS016 in Hospitalized Chinese Patients with COVID-19: a Phase 2/3, Multicenter, Randomized, Open-Label, Controlled Trial.新型冠状病毒中和抗体 JS016 治疗住院 COVID-19 患者的疗效和安全性：一项 2/3 期、多中心、随机、开放标签、对照临床试验。
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0204521. doi: 10.1128/AAC.02045-21.
5
Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.COVID-19 的抗病毒治疗：基于过去抗病毒和法匹拉韦经验的最佳策略推导。
Pharmacol Ther. 2022 Jul;235:108121. doi: 10.1016/j.pharmthera.2022.108121. Epub 2022 Feb 1.
6
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.大剂量伊维菌素早期治疗 COVID-19（COVER 研究）：一项随机、双盲、多中心、II 期、剂量探索、概念验证临床试验。
Int J Antimicrob Agents. 2022 Feb;59(2):106516. doi: 10.1016/j.ijantimicag.2021.106516. Epub 2022 Jan 6.
7
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.社论：非住院患者 SARS-CoV-2 感染的口服抗病毒药物治疗现状。
Med Sci Monit. 2022 Jan 1;28:e935952. doi: 10.12659/MSM.935952.
8
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.根据基线抗体和抗原水平，对 COVID-19 住院患者使用中和单克隆抗体的反应：一项随机对照试验。
Ann Intern Med. 2022 Feb;175(2):234-243. doi: 10.7326/M21-3507. Epub 2021 Dec 21.
9
Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome.COVID-19 急性呼吸窘迫综合征中抗人 LIGHT 单克隆抗体的随机、双盲、对照试验。
J Clin Invest. 2022 Feb 1;132(3). doi: 10.1172/JCI153173.
10
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.伦齐单抗治疗 COVID-19 肺炎住院患者（LIVE-AIR）：一项 3 期、随机、安慰剂对照试验。
Lancet Respir Med. 2022 Mar;10(3):237-246. doi: 10.1016/S2213-2600(21)00494-X. Epub 2021 Dec 1.
Zotero 插件